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Background
Vaccinations in the Step Study, designed to assess the effi-
cacy of a T cell-based vaccine, were interrupted in 2007
after an interim analysis showed no evidence of efficacy. 
Methods
To evaluate the impact of the vaccine on founder/break-
through viruses, i.e., the viruses obtained from the earliest
available specimen around the time of diagnosis, we
obtained 0.5-14 HIV-1 whole genome sequences per indi-
vidual from 40 vaccine and 28 placebo recipients who
acquired HIV-1 infection as of December 2007. 
Results
To assess whether the vaccine elicited T cells that exerted
selective pressure on founder viruses, we identified known
and likely class I MHC-restricted CTL epitopes in founder
sequences based on each volunteer’s HLA type. We calcu-
lated protein distances between epitopes in the vaccine
and those in the founder sequences. Compared to the vac-
cine, epitopes from vaccine recipients exhibited more
mutations than epitopes from placebo recipients
(p=0.02). Potential epitopes were then identified across
all infected individuals and compared to HXB2. The
epitopic distances from the combination of Gag, Pol and
Nef sequences (included in vaccine) were significantly
higher among vaccine vs. placebo recipients (p=0.004). In
contrast, there was no distinction between vaccine and
placebo if epitopes from Env, Rev, Tat, Vif, Vpr, Vpu (not
included in vaccine) were considered together (p=0.90).
Lastly, ~10 AA signature sites in Gag, Nef, Pol (but none
in Env) were found to classify vaccine versus placebo sta-
tus. 
Conclusion
Our data indicate that founder viruses from vaccinees
diverged further from the vaccine than viruses from pla-
cebo recipients at potentially immune reactive sites. This
suggests that the vaccine may have blocked the outgrowth
of specific HIV-1 variants that were the most similar to the
vaccine sequence and/or elicited immune responses that
may have driven specific mutations among vaccinees’
viruses post-infection.
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